About clonoSEQ

A test that’s as mighty as today’s cancer treatments

clonoSEQ is a blood or bone marrow test1 that measures your cancer at the deepest level currently available1-3, helping your doctor make more informed decisions about your care. It is FDA-cleared in bone marrow and CLIA-validated in peripheral blood for B-cell acute lymphoblastic leukemia (B-ALL).

clonoSEQ is a blood or bone marrow test1 that measures your cancer at the deepest level currently available1-3, helping your doctor make more informed decisions about your care. It is FDA-cleared in bone marrow and CLIA-validated in peripheral blood for B-cell acute lymphoblastic leukemia (B-ALL).

clonoSEQ helps your doctor tailor treatment to your needs

clonoSEQ uses next-generation sequencing technology, an advanced testing method that decodes your cancer’s genetic information, to look for unique cancer DNA sequences that serve as “barcodes.” After your diagnosis, clonoSEQ identifies and counts your cancer’s unique “barcodes.” During treatment and remission, clonoSEQ can tell you and your doctor if and how the number of “barcodes” has changed since your last MRD test.1

clonoSEQ is covered by Medicare and other major insurance providers

“If there was one word to describe receiving my MRD results, I would say, hope.”

— Tiffany, a blood cancer patient who had clonoSEQ testing

clonoSEQ can find 1 cancer cell among a million healthy cells1*

What does 1 in a million mean to you? It means that you and your doctor know exactly where you are on your blood cancer journey. And when it comes to cancer, knowledge is power. By precisely tracking MRD both during and after treatment, you and your doctor can be more informed about your response to therapy—and can plan next steps accordingly.

*If sufficient sample material is provided.

clonoSEQ can identify residual disease that other tests miss4

Your doctor will likely order other tests—like flow tests or routine blood work—to monitor your cancer. This is a good thing! It means your doctor is trying to gather as much useful information as possible. To best understand how your cancer may be changing over time, these tests can be paired with a highly sensitive MRD testing tool like clonoSEQ.2-7

clonoSEQ detected MRD in

46%

of patients who were deemed
MRD-negative by a flow test4

Measure, then treat. Treat, then measure.
Repeat throughout your journey.

There are several stages of treatment for ALL. Your doctor may want to check your MRD status after each one, to see how effective your treatment was. Your clonoSEQ results may guide which treatment comes next.

Click through to see when your doctor may test you with clonoSEQ.

(1 of 5)

Initial diagnosis1

Identify cancer cell DNA
(Clonality (ID) Test)
The clonoSEQ Clonality (ID) Test provides a baseline. Because this test is done on the largest number of cancer cells, it helps clonoSEQ know which cells to look for in later tests.

Your doctor may want to continue frequently monitoring MRD status with clonoSEQ, whether or not you are on maintenance therapy. Your MRD status can help you and your doctor feel secure, knowing that if your ALL returns, you can treat it immediately.

Talk to your doctor about clonoSEQ

Here are some questions to help you start a conversation with your doctor.

  • Is MRD testing with clonoSEQ right for me?
  • I heard that clonoSEQ can identify 1 cancer cell out of a million cells with sufficient sample provided. Why does that matter for me?
  • What can MRD testing with clonoSEQ tell me about my cancer?
  • How will you incorporate my MRD results with clonoSEQ into my treatment plan?
  • At what points during the treatment process should I have a clonoSEQ MRD test?
  • Is clonoSEQ testing covered by insurance?

Be sure to check in with your doctor regularly. This way, you can ensure you are on track with the MRD goals you’ve set together.

Take a look at a sample clonoSEQ report

Sample clonoSEQ Report

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020.
  2. Short NJ, et al. Am J Hematol. 2019;94:257-265.
  3. Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
  4. Short N, et al. Blood Adv. 2022;6(13):4006-4014.
  5. Wood B, et al. Blood. 2018;131(12):1350-1359.
  6. Pulsipher M, et al. Blood. 2015;125(22):3501-3508.
  1. Pulsipher M, et al. Blood Cancer Discov. 2022;3(1):66-81.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.